Monday, December 13, 2021 Daily Archives

Rethinking Chromatography

by and

Dynamic trends in the biotherapeutic industry are shifting manufacturers towards new modalities and intensified production strategies. This development is supported by ongoing scientific and technical advances in both upstream and downstream processing steps. Downstream processing of new modalities requires chromatography technologies that can handle large, fragile molecules (such as mRNA and viral particles). To maximize speed and productivity, platforms supporting continuous processing will become essential. In this feature, Sartorius discusses current and future concerns for process chromatography operations. They then…

December 13, 2021

Doer to develop multi-specific biotherapeutics using Lonza’s technology

by

Doer Biologics has signed a licensing agreement with Lonza to use its XS Pichia Expression System to produce multi-specific biotherapeutics. Under the terms of the deal, Chinese clinical-stage biopharmaceutical firm Doer will have access to Lonza’s XS technologies services for production of its proprietary MultipleBody and SMART-VHHBody platform technology. According to contract development manufacturing organization (CDMO) Lonza, its XS Pichia Expression System can provide “scalable, robust, and reliable expression processes,” which will support Doer to develop Volatile Halogenated Hydrocarbons (VHH)-based…

December 13, 2021

Ampersand backs Alliance Pharma and plans ‘aggressive’ growth plan

by

Private equity firm Ampersand Capital Partners has invested in bioanalytical services contractor, Alliance Pharma. Financial terms of the investment were not disclosed. Ampersand confirmed that company founder and president, Frank Li, will remain a significant shareholder in Alliance. Malvern, Pennsylvania-headquartered Alliance provides discovery bioanalytical, DMPK, regulated bioanalysis, biomarker, LC-MS/MS, immunoassay services as well as cell and gene therapy and protein characterization. The firm works on all stages of drug development from animal studies through all phases of clinical development. It…

December 13, 2021

Evolve to build plasma plant in Texas

by

Evolve Biologics has chosen Sachse, Texas as the site of its first plasma-derived therapeutics facility. Canadian-headquartered firm Evolve says the site selection and purchase of land establishes the company’s drive towards the commercialization of plasma-derived therapeutics. “Northern Texas has a growing corporate/pharmaceutical presence which enables collaboration and attracts a highly skilled workforce. The Dalls Fort Worth area also has a very strong educational base, including many high caliber and local universities, which is great for recruiting,†said David Holliday, Chief…

December 13, 2021